{"protocolSection":{"identificationModule":{"nctId":"NCT03060629","orgStudyIdInfo":{"id":"CR108263"},"secondaryIdInfos":[{"id":"VAC89220HPX2008","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"HVTN 705","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"HVTN 705/VAC89220HPX2008","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa"},"statusModule":{"statusVerifiedDate":"2023-03","overallStatus":"TERMINATED","whyStopped":"Study was terminated by the sponsor after the last participant completed the Month 24 visit as the pre-specified criteria to continue the study were not met.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-11-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-02-02","type":"ACTUAL"},"completionDateStruct":{"date":"2022-02-02","type":"ACTUAL"},"studyFirstSubmitDate":"2017-02-17","studyFirstSubmitQcDate":"2017-02-17","studyFirstPostDateStruct":{"date":"2017-02-23","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-02-02","resultsFirstSubmitQcDate":"2023-03-24","resultsFirstPostDateStruct":{"date":"2023-04-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-03-24","lastUpdatePostDateStruct":{"date":"2023-04-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary purpose of this study is to assess the preventive vaccine efficacy (VE), safety and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and aluminum-phosphate adjuvanted Clade C gp 140 for the prevention of Human Immuno Virus (HIV) infection in HIV-seronegative women residing in sub-Saharan Africa from confirmed HIV-1 infections diagnosed between the Month 7 and Month 24 visits."},"conditionsModule":{"conditions":["HIV-1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Sponsor will be also blinded","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":2636,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","description":"Participants will receive Ad26.Mos4.HIV 5\\*10\\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 \\[microgram\\] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.","interventionNames":["Biological: Ad26.Mos4.HIV","Biological: Clade C gp140"]},{"label":"Group 2","type":"PLACEBO_COMPARATOR","description":"Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.Mos4.HIV","description":"Participants will receive Ad26.Mos4.HIV 5x10\\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.","armGroupLabels":["Group 1"]},{"type":"BIOLOGICAL","name":"Clade C gp140","description":"Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.","armGroupLabels":["Group 1"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Participants will receive matching placebo.","armGroupLabels":["Group 2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed between Month 7 to Month 24 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"Month 7 up to Month 24"},{"measure":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After First Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after first vaccination were reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","timeFrame":"Up to 7 days after first vaccination on Day 0 (Day 7)"},{"measure":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After Second Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after second vaccination was reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","timeFrame":"Up to 7 days after second vaccination on Day 84 (Day 91)"},{"measure":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After Third Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after third vaccination was reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","timeFrame":"Up to 7 days after third vaccination on Day 168 (Up to Day 175)"},{"measure":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After Fourth Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after fourth vaccination was reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","timeFrame":"Up to 7 days after fourth vaccination on Day 364 (Up to Day 371)"},{"measure":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After First Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after first vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","timeFrame":"Up to 7 days after first vaccination on Day 0 (Day 7)"},{"measure":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Second Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after second vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","timeFrame":"Up to 7 days after second vaccination on Day 84 (Day 91)"},{"measure":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Third Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after third vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","timeFrame":"Up to 7 days after third vaccination on Day 168 (Up to Day 175)"},{"measure":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Fourth Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after fourth vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","timeFrame":"Up to 7 days after fourth vaccination on Day 364 (Up to Day 371)"},{"measure":"Percentage of Participants With Unsolicited Adverse Events (AEs) for 30 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","timeFrame":"30 days after first vaccination on Day 0 (Up to Day 30)"},{"measure":"Percentage of Participants With Unsolicited AEs for 30 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","timeFrame":"30 days after second vaccination on Day 84 (Up to Day 114)"},{"measure":"Percentage of Participants With Unsolicited AEs for 30 Days After Third Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","timeFrame":"30 days after third vaccination on Day 168 (Up to Day 198)"},{"measure":"Percentage of Participants With Unsolicited AEs for 30 Days After Fourth Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","timeFrame":"30 days after fourth vaccination on Day 364 (Up to Day 394)"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","timeFrame":"Up to Month 36 (up to end of the study)"},{"measure":"Percentage of Participants With Adverse Events of Special Interest (AESIs)","description":"Percentage of participants with AESIs was reported. Immune-mediated diseases were considered as AESIs in this study.","timeFrame":"Up to Month 36 (up to end of the study)"},{"measure":"Percentage of Participants With AEs Leading to Early Participant Withdrawal or Early Discontinuation of Study Product","description":"Percentage of participants with AEs leading to early participant withdrawal or early discontinuation of study product were reported. An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with this treatment.","timeFrame":"Up to Month 36 (up to end of the study)"}],"secondaryOutcomes":[{"measure":"Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 24 Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from enrollment (baseline) through month 24 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"Baseline up to Month 24"},{"measure":"Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 36 (End of Study) Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from enrollment (baseline) through Month 36 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"Baseline up to Month 36 (End of study)"},{"measure":"Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 24 Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from Month 13 through Month 24 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"Month 13 up to Month 24"},{"measure":"Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 36 (End of Study) Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from Month 13 through Month 36 (end of study) post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","timeFrame":"Month 13 up to Month 36 (End of study)"},{"measure":"Geometric Mean of Binding Antibody Responses to HIV Envelop (ENV) Clade (gp140) C (ZA) Analyzed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"A weighted geometric mean of the binding antibody responses to HIV envelope (ENV) gp140 Clade C 97ZA protein analyzed by ELISA was reported.","timeFrame":"Months 0, 7, 13 and 24"},{"measure":"Geometric Mean of Interferon-gamma (IFN-gamma) T-Cells Responses Analyzed by Enzyme-linked Immunospot Assay (ELISpot)","description":"Geometric mean of IFN-gamma T-cells responses analyzed by ELISpot were reported. A weighted geometric mean of the number of spot-forming cells (SFC) per million peripheral blood mononuclear cells (PBMCs) producing Interferon-gamma upon stimulation with potential T-cell epitope (PTE) ENV peptide pools analyzed by ELISpot was reported. Reported responses are the sum of the number of SFCs/10\\^6 PBMCS for PTE Env1, Env2 and Env3 sub-pools.","timeFrame":"Months 0, 7, 13 and 24"},{"measure":"Number of Participants With Viral Sequences","description":"Number of participants with viral sequences were reported. Viral sequencing was conducted on the earliest available plasma specimens with positive HIV-1 ribose nucleic acid polymerase chain reaction (RNA PCR) tests from study participants who were diagnosed with HIV-1 infection.","timeFrame":"Month 7 up to Month 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sexually active, defined as having had sexual intercourse with a male partner at least twice in the past 30 days prior to screening, and is considered by the site staff to be at risk for Human Immunodeficiency Virus (HIV) infection\n* Access to a participating HIV Vaccine Trials Network (HVTN) Clinical Research Sites (CRS) and willingness to be followed for the planned duration of the study\n* Willingness to discuss HIV infection risks and willing to receive HIV risk reduction counseling and appropriate referrals to minimize HIV acquisition, as applicable\n* Negative beta human chorionic gonadotropin (beta-HCG) pregnancy test performed prior to vaccination on the day of initial vaccination. Persons who are NOT of reproductive potential due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records), are not required to undergo pregnancy testing\n* Participants must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until 3 months after the last vaccination\n\nExclusion Criteria:\n\n* Investigational research agents received within 30 days before first vaccination\n* HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 705/HPX2008 (Protocol Safety Review Team) PSRT will determine eligibility on a case-by-case basis\n* Live attenuated vaccines received within 30 days before first vaccination or scheduled within 14 days after injection (example: measles, mumps, and rubella \\[MMR\\]; oral polio vaccine \\[OPV\\]; varicella; yellow fever)\n* Any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (example, tetanus, pneumococcal, Hepatitis A or B)\n* Immunosuppressive medications received within 6 months before first vaccination","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"UNC Lilongwe Project","city":"Lilongwe","country":"Malawi","geoPoint":{"lat":-13.96692,"lon":33.78725}},{"facility":"Polana Caniço Health Research and Training Center (CISPOC)","city":"Maputo","country":"Mozambique","geoPoint":{"lat":-25.96553,"lon":32.58322}},{"facility":"Josha Research","city":"Bloemfontein","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"facility":"Masiphumelele Research Centre","city":"Cape Town","zip":"7975","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Ndlovu Elandsdoorn Site","city":"Dennilton","zip":"0485","country":"South Africa","geoPoint":{"lat":-25.28209,"lon":29.15331}},{"facility":"Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital","city":"Diepkloof","zip":"1862","country":"South Africa","geoPoint":{"lat":-26.24358,"lon":27.9505}},{"facility":"Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital","city":"Johannesburg","zip":"1862","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"The Aurum Institute Klerksdorp Clinical Research Centre","city":"Klerksdorp","zip":"2571","country":"South Africa","geoPoint":{"lat":-26.85213,"lon":26.66672}},{"facility":"Qhakaza Mbokodo Research Centre","city":"KwaZulu-Natal","zip":"4030","country":"South Africa"},{"facility":"South African Medical Research Council Chatsworth Clinical Research Site","city":"KwaZulu-Natal","zip":"4030","country":"South Africa"},{"facility":"Centre for the AIDS Programme of Research in South Africa","city":"KwaZulu-Natal","zip":"4110","country":"South Africa"},{"facility":"South African Medical Research Council Tongaat Clinical Research Site","city":"KwaZulu-Natal","zip":"4399","country":"South Africa"},{"facility":"Stanza Clinical Research Centre : Mamelodi","city":"Mamelodi East","zip":"122","country":"South Africa","geoPoint":{"lat":-25.67912,"lon":28.35096}},{"facility":"Nelson Mandela Academic Clinical Research Unit 'NeMACRU'","city":"Mthatha","zip":"5099","country":"South Africa","geoPoint":{"lat":-31.58893,"lon":28.78443}},{"facility":"MeCRU Clinical Research Unit","city":"Pretoria","zip":"204","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"The Aurum Institute Rustenburg Clinical Research Site","city":"Rustenburg","zip":"300","country":"South Africa","geoPoint":{"lat":-25.66756,"lon":27.24208}},{"facility":"Setshaba Research Centre","city":"Soshanguve","zip":"152","country":"South Africa","geoPoint":{"lat":-25.47288,"lon":28.09919}},{"facility":"The Aurum Institute: Tembisa - Clinic 4","city":"Tembisa","zip":"1632","country":"South Africa","geoPoint":{"lat":-26.00979,"lon":28.22762}},{"facility":"Centre for Infectious Disease Research in Zambia (CIDRZ)","city":"Lusaka","zip":"10101","country":"Zambia","geoPoint":{"lat":-15.40669,"lon":28.28713}},{"facility":"Center for Family Health Research in Zambia (CFHRZ)","city":"Lusaka","zip":"P/BagE891","country":"Zambia","geoPoint":{"lat":-15.40669,"lon":28.28713}},{"facility":"Center for Family Health Research in Zambia (CFHRZ)","city":"Ndola","zip":"240262","country":"Zambia","geoPoint":{"lat":-12.95867,"lon":28.63659}},{"facility":"St Mary's Clinic","city":"Chitungwiza","country":"Zimbabwe","geoPoint":{"lat":-18.01274,"lon":31.07555}},{"facility":"University of Zimbabwe-UCSF","city":"Harare - Seke South","country":"Zimbabwe"}]},"referencesModule":{"references":[{"pmid":"40190112","type":"DERIVED","citation":"Moodie Z, Li SS, Giorgi EE, Williams LD, Dintwe O, Carpp LN, Chen S, Seaton KE, Sawant SS, Zhang L, Heptinstall J, Liu S, Grunenberg N, Tomaka F, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Ake JA, Vasan S, Pantaleo G, Frank I, Baden LR, Goepfert PA, Keefer M, Chirenje M, Hosseinipour MC, Mngadi K, Laher F, Garrett N, Bekker LG, De Rosa S, Andersen-Nissen E, Kublin JG, Lu S, Gilbert PB, Gray GE, Corey L, McElrath MJ, Tomaras GD. A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. Emerg Microbes Infect. 2025 Dec;14(1):2485317. doi: 10.1080/22221751.2025.2485317. Epub 2025 Apr 7."},{"pmid":"39038477","type":"DERIVED","citation":"Gray GE, Mngadi K, Lavreys L, Nijs S, Gilbert PB, Hural J, Hyrien O, Juraska M, Luedtke A, Mann P, McElrath MJ, Odhiambo JA, Stieh DJ, van Duijn J, Takalani AN, Willems W, Tapley A, Tomaras GD, Van Hoof J, Schuitemaker H, Swann E, Barouch DH, Kublin JG, Corey L, Pau MG, Buchbinder S, Tomaka F; Imbokodo/HVTN 705/HPX2008 Study Group. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2024 Nov;24(11):1201-1212. doi: 10.1016/S1473-3099(24)00358-X. Epub 2024 Jul 19."},{"pmid":"30047376","type":"DERIVED","citation":"Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"For Participant Flow below, data were summarized based on assigned treatment.","groups":[{"id":"FG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"FG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1313"},{"groupId":"FG001","numSubjects":"1323"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"78"},{"groupId":"FG001","numSubjects":"88"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1235"},{"groupId":"FG001","numSubjects":"1235"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"35"}]},{"type":"Unable to Adhere to Visit Schedule","reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"Participant Relocate","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Unable to Contact Participant","reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"Investigator Decision","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"1100"},{"groupId":"FG001","numSubjects":"1123"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"BG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1313"},{"groupId":"BG001","value":"1323"},{"groupId":"BG002","value":"2636"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22","lowerLimit":"18","upperLimit":"35"},{"groupId":"BG001","value":"23","lowerLimit":"18","upperLimit":"35"},{"groupId":"BG002","value":"23","lowerLimit":"18","upperLimit":"35"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1313"},{"groupId":"BG001","value":"1323"},{"groupId":"BG002","value":"2636"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1313"},{"groupId":"BG001","value":"1323"},{"groupId":"BG002","value":"2636"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"1302"},{"groupId":"BG001","value":"1317"},{"groupId":"BG002","value":"2619"}]}]},{"title":"Colored/Mixed","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}]},{"title":"Indian","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]},{"title":"Multiple","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"MALAWI","categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"157"}]}]},{"title":"MOZAMBIQUE","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"45"}]}]},{"title":"SOUTH AFRICA","categories":[{"measurements":[{"groupId":"BG000","value":"882"},{"groupId":"BG001","value":"892"},{"groupId":"BG002","value":"1774"}]}]},{"title":"ZAMBIA","categories":[{"measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"329"}]}]},{"title":"ZIMBABWE","categories":[{"measurements":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"331"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed between Month 7 to Month 24 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"Per protocol (PP) population set included participants from the full analysis set (FAS; all randomized participants who received at least one study vaccine administration) who were HIV-1 uninfected 4 weeks after the third vaccination visit, who received all planned vaccinations at the first 3 vaccination visits within the respective visit windows and had no other major protocol deviations that were judged to possibly impact the efficacy of the vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 up to Month 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1080"},{"groupId":"OG001","value":"1108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"65"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After First Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after first vaccination were reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. The safety analyses were performed based on the actual treatment that the participants received after the first vaccination. Hence, one participant from Group 2 was analyzed in Group 1 for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after first vaccination on Day 0 (Day 7)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1316"},{"groupId":"OG001","value":"1320"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2"},{"groupId":"OG001","value":"9.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After Second Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after second vaccination was reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after second vaccination on Day 84 (Day 91)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1190"},{"groupId":"OG001","value":"1215"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"8.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After Third Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after third vaccination was reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after third vaccination on Day 168 (Up to Day 175)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1160"},{"groupId":"OG001","value":"1188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2"},{"groupId":"OG001","value":"8.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactogenicity Signs and Symptoms After Fourth Vaccination","description":"Percentage of participants with local reactogenicity signs and symptoms after fourth vaccination was reported. Local reactogenicity events (solicited local adverse events) were defined as events at the injection site. Local reactogenicity signs and symptoms included pain and/or tenderness proximal to the injection site.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after fourth vaccination on Day 364 (Up to Day 371)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1099"},{"groupId":"OG001","value":"1111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7"},{"groupId":"OG001","value":"8.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After First Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after first vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. The safety analyses were performed based on the actual treatment that the participants received after the first vaccination. Hence, one participant from Group 2 was analyzed in Group 1 for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after first vaccination on Day 0 (Day 7)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1316"},{"groupId":"OG001","value":"1320"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9"},{"groupId":"OG001","value":"40.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Second Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after second vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after second vaccination on Day 84 (Day 91)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1190"},{"groupId":"OG001","value":"1215"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2"},{"groupId":"OG001","value":"28.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Third Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after third vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after third vaccination on Day 168 (Up to Day 175)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1160"},{"groupId":"OG001","value":"1188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5"},{"groupId":"OG001","value":"26.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Fourth Vaccination","description":"Percentage of participants with systematic reactogenicity signs and symptoms after fourth vaccination was reported. Systemic reactogenicity events (solicited systemic adverse events) defined as events occurred in a predefined post-vaccination period for which the subject was specifically questioned. Systemic reactogenicity signs and symptoms included increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 7 days after fourth vaccination on Day 364 (Up to Day 371)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1099"},{"groupId":"OG001","value":"1111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4"},{"groupId":"OG001","value":"23.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited Adverse Events (AEs) for 30 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. The safety analyses were performed based on the actual treatment that the participants received after the first vaccination. Hence, one participant from Group 2 was analyzed in Group 1 for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"30 days after first vaccination on Day 0 (Up to Day 30)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1316"},{"groupId":"OG001","value":"1320"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6"},{"groupId":"OG001","value":"14.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 30 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"30 days after second vaccination on Day 84 (Up to Day 114)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1190"},{"groupId":"OG001","value":"1215"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1"},{"groupId":"OG001","value":"15.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 30 Days After Third Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"30 days after third vaccination on Day 168 (Up to Day 198)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1160"},{"groupId":"OG001","value":"1188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8"},{"groupId":"OG001","value":"40.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 30 Days After Fourth Vaccination","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. The most frequent unsolicited AEs were upper respiratory tract infection, back pain, cough, and hypertension.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"30 days after fourth vaccination on Day 364 (Up to Day 394)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1099"},{"groupId":"OG001","value":"1111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5"},{"groupId":"OG001","value":"62.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with the study treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. The safety analyses were performed based on the actual treatment that the participants received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Month 36 (up to end of the study)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1317"},{"groupId":"OG001","value":"1319"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7"},{"groupId":"OG001","value":"2.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events of Special Interest (AESIs)","description":"Percentage of participants with AESIs was reported. Immune-mediated diseases were considered as AESIs in this study.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. The safety analyses were performed based on the actual treatment that the participants received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Month 36 (up to end of the study)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1317"},{"groupId":"OG001","value":"1319"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs Leading to Early Participant Withdrawal or Early Discontinuation of Study Product","description":"Percentage of participants with AEs leading to early participant withdrawal or early discontinuation of study product were reported. An AE is any untoward medical occurrence in a clinical investigation participant administered a study product and which does not necessarily have a causal relationship with this treatment.","populationDescription":"FAS included all randomized participants who received at least 1 vaccine administration. The safety analyses were performed based on the actual treatment that the participants received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Month 36 (up to end of the study)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1317"},{"groupId":"OG001","value":"1319"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 24 Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from enrollment (baseline) through month 24 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"Modified Intent-to-Treat (MITT) analysis set included participants in the FAS who were HIV-1 uninfected on the date of first vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Month 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1311"},{"groupId":"OG001","value":"1319"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"102"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 36 (End of Study) Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from enrollment (baseline) through Month 36 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"MITT analysis set included participants in the FAS who were HIV-1 uninfected on the date of first vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline up to Month 36 (End of study)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1311"},{"groupId":"OG001","value":"1319"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"127"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 24 Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from Month 13 through Month 24 post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"Full immunization set (FIS) included participants in the FAS who were HIV-1 uninfected 4 week after the fourth vaccination visit and who received all planned vaccinations within the respective visit windows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 13 up to Month 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"981"},{"groupId":"OG001","value":"995"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"35"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 36 (End of Study) Post Enrollment","description":"Number of participants with HIV-1 infection diagnosed from Month 13 through Month 36 (end of study) post enrollment was reported. The data represents the cumulative incidence of HIV-1 infections.","populationDescription":"FIS included participants in the FAS who were HIV-1 uninfected 4 week after the fourth vaccination visit and who received all planned vaccinations within the respective visit windows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 13 up to Month 36 (End of study)","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"981"},{"groupId":"OG001","value":"995"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"58"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean of Binding Antibody Responses to HIV Envelop (ENV) Clade (gp140) C (ZA) Analyzed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"A weighted geometric mean of the binding antibody responses to HIV envelope (ENV) gp140 Clade C 97ZA protein analyzed by ELISA was reported.","populationDescription":"FIS included participants in the FAS who were HIV-1 uninfected 4 weeks after the fourth vaccination visit and who received all planned vaccinations within the respective visit windows. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ELISA Units per milliliter (EU/mL)","timeFrame":"Months 0, 7, 13 and 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"10"}]}],"classes":[{"title":"Month 0","categories":[{"measurements":[{"groupId":"OG000","value":"53","lowerLimit":"45","upperLimit":"63"},{"groupId":"OG001","value":"43","lowerLimit":"37","upperLimit":"49"}]}]},{"title":"Month 7","categories":[{"measurements":[{"groupId":"OG000","value":"38834","lowerLimit":"26484","upperLimit":"56942"},{"groupId":"OG001","value":"43","lowerLimit":"37","upperLimit":"49"}]}]},{"title":"Month 13","categories":[{"measurements":[{"groupId":"OG000","value":"66147","lowerLimit":"50523","upperLimit":"86602"},{"groupId":"OG001","value":"62","lowerLimit":"36","upperLimit":"109"}]}]},{"title":"Month 24","categories":[{"measurements":[{"groupId":"OG000","value":"5920","lowerLimit":"4559","upperLimit":"7688"},{"groupId":"OG001","value":"49","lowerLimit":"33","upperLimit":"72"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean of Interferon-gamma (IFN-gamma) T-Cells Responses Analyzed by Enzyme-linked Immunospot Assay (ELISpot)","description":"Geometric mean of IFN-gamma T-cells responses analyzed by ELISpot were reported. A weighted geometric mean of the number of spot-forming cells (SFC) per million peripheral blood mononuclear cells (PBMCs) producing Interferon-gamma upon stimulation with potential T-cell epitope (PTE) ENV peptide pools analyzed by ELISpot was reported. Reported responses are the sum of the number of SFCs/10\\^6 PBMCS for PTE Env1, Env2 and Env3 sub-pools.","populationDescription":"FIS included participants who were HIV-1 uninfected 4 week after the fourth vaccination visit and who received all planned vaccinations within the respective visit windows. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) signifies number of participants who were analyzed at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"SFC/million PBMCs","timeFrame":"Months 0, 7, 13 and 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"10"}]}],"classes":[{"title":"Month 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","lowerLimit":"29.7","upperLimit":"33.7"},{"groupId":"OG001","value":"30.0","lowerLimit":"30.0","upperLimit":"30.0"}]}]},{"title":"Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"241.2","lowerLimit":"168.0","upperLimit":"346.2"},{"groupId":"OG001","value":"33.9","lowerLimit":"26.7","upperLimit":"43.0"}]}]},{"title":"Month 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"287.1","lowerLimit":"201.3","upperLimit":"409.5"},{"groupId":"OG001","value":"33.2","lowerLimit":"28.8","upperLimit":"38.2"}]}]},{"title":"Month 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"172.7","lowerLimit":"117.0","upperLimit":"254.8"},{"groupId":"OG001","value":"30.8","lowerLimit":"29.2","upperLimit":"32.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Viral Sequences","description":"Number of participants with viral sequences were reported. Viral sequencing was conducted on the earliest available plasma specimens with positive HIV-1 ribose nucleic acid polymerase chain reaction (RNA PCR) tests from study participants who were diagnosed with HIV-1 infection.","populationDescription":"PP population set included participants from the FAS; all randomized participants who received at least one study vaccine administration) who were HIV-1 uninfected 4 weeks after the third vaccination visit, who received all planned vaccinations at the first 3 vaccination visits within the respective visit windows and had no other major protocol deviations that were judged to possibly impact the efficacy of the vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Month 7 up to Month 24","groups":[{"id":"OG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12."},{"id":"OG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1080"},{"groupId":"OG001","value":"1108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"63"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Month 36","description":"Full analysis set (FAS) included all randomized participants who received at least 1 vaccine administration. Here, N (total number of participants at risk) signifies participants who were assessed for AEs as safety analyses were performed based on the actual treatment that the participants received. Therefore, number of participants affected for all-cause mortality are different in participant flow section and adverse event section.","eventGroups":[{"id":"EG000","title":"Group 1: Ad26.Mos.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\\*10\\^10 virus particles (vp) per 0.5 milliliter (mL) via Intramuscular (IM) injection at Months 0, 3, 6, and 12 and Clade C glycoprotein (gp) 140 (250 \\[micrograms\\] mcg) mixed with aluminum phosphate adjuvant 425 mcg per 0.5 mL IM injection at Months 6 and 12.","deathsNumAffected":5,"deathsNumAtRisk":1317,"seriousNumAffected":49,"seriousNumAtRisk":1317,"otherNumAffected":798,"otherNumAtRisk":1317},{"id":"EG001","title":"Group 2: Placebo","description":"Participants received Placebo matching to Ad26.Mos4.HIV as 0.5 mL via IM injection at Months 0, 3, 6, and 12 and Placebo matching to Clade C gp140/aluminum phosphate adjuvant as 0.5 mL IM injection at Months 6 and 12.","deathsNumAffected":4,"deathsNumAtRisk":1319,"seriousNumAffected":37,"seriousNumAtRisk":1319,"otherNumAffected":806,"otherNumAtRisk":1319}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Congenital anomaly in offspring","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":2,"numAtRisk":1319}]},{"term":"Abdominal mass","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Immune reconstitution inflammatory syndrome","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Gonococcal pelvic inflammatory disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"HIV-associated neurocognitive disorder","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Pelvic inflammatory disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":2,"numAtRisk":1319}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Salmonella sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Wound sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Accidental exposure to product","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Chemical poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Crush injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Eye injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Jaw fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Stab wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Alcohol intolerance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":3,"numAtRisk":1319}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Cerebral cyst","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Idiopathic intracranial hypertension","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Psychogenic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Abortion incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1317},{"groupId":"EG001","numAffected":2,"numAtRisk":1319}]},{"term":"Anembryonic gestation","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"False labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Foetal death","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Maternal death during childbirth","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Preterm premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Alcoholic psychosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Intentional self-injury","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":2,"numAtRisk":1319}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1317},{"groupId":"EG001","numAffected":1,"numAtRisk":1319}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1317},{"groupId":"EG001","numAffected":0,"numAtRisk":1319}]}],"otherEvents":[{"term":"Genitourinary chlamydia infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":528,"numAtRisk":1317},{"groupId":"EG001","numAffected":527,"numAtRisk":1319}]},{"term":"Genitourinary tract gonococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":269,"numAtRisk":1317},{"groupId":"EG001","numAffected":288,"numAtRisk":1319}]},{"term":"Syphilis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":1317},{"groupId":"EG001","numAffected":79,"numAtRisk":1319}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":79,"numAtRisk":1317},{"groupId":"EG001","numAffected":77,"numAtRisk":1319}]},{"term":"Vulvovaginitis trichomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":245,"numAtRisk":1317},{"groupId":"EG001","numAffected":239,"numAtRisk":1319}]},{"term":"Vaginal discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":102,"numAtRisk":1317},{"groupId":"EG001","numAffected":113,"numAtRisk":1319}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."},"pointOfContact":{"title":"CLINICAL FRANCHISE LEADER","organization":"Janssen Vaccines & Prevention B.V","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-06-12","uploadDate":"2023-02-02T10:09","filename":"Prot_000.pdf","size":2948009},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-06-30","uploadDate":"2023-02-02T10:09","filename":"SAP_001.pdf","size":2596170}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-03-03","type":"ACTUAL"}}}}},"hasResults":true}